Author

Haiqing Hua

Observed name: Hua, Haiqing

Institution: Duality Biotherapeutics, Inc. (China)

Observed institution: Duality Biotherapeutics, Inc. (China)

ORCID: 0000-0002-6714-0708

Observed ORCID: 0000-0002-6714-0708

OpenAlex ID: A5125327253

IL1RAP Antibody–Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers

2026 · Hai-Feng Zhang, Edouard De Dreuzy, et al. · Cancer Discovery · 2

Data from Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti–B7-H3 × PD-L1 Antibody–Drug Conjugate

2025 · Chenggang Li, Jun Yao, et al. · 1

Abstract CT086: A phase 1/2, first-in-human study of an ADC targeting CDH17 (DB-1324) in participants with advanced/metastatic gastrointestinal tumor

2026 · Lin Shen, Jifang Gong, et al. · Cancer Research

Abstract 2655: DB-1323, a next-generation mesothelin targeting antibody-drug conjugate, demonstrated anti-tumor activity and favorable safety profile in pre-clinical models

2026 · Haiqing Hua, Xi Li, et al. · Cancer Research

Abstract 2656: DB-1329: A novel antibody-drug conjugate targeting CDCP1 demonstrates potent preclinical anti-tumor activity across multiple solid tumors

2026 · Hui Yang, Yujie Liu, et al. · Cancer Research

Abstract 2657: DB-1326, a novel dual-payload TA-MUC1-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model

2026 · Chenggang Li, Lei Yi, et al. · Cancer Research

Abstract 2654: DB-1421, an optimized EGFR/MUC1 bispecific ADC, exhibits improved tumor selectivity, promising efficacy and safety in preclinical studies

2026 · Chenggang Li, Jun Yao, et al. · Cancer Research

Works count: 9

Citation count: 3

H-index: 1

I10-index: